Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Torsten Haferlach

Showing results (121-130 of 596) with videos related to

Pageof 60
Sort By:
Medizinische Klinik (Munich, Germany : 1983)|January 20, 2007
[Microarrays and gene expression profiling for the diagnosis in leukemia. From research studies to routine application]Torsten Haferlach, Ulrike Bacher, Alexander Kohlmann, et al.
British Journal of Haematology|July 21, 2005
Impact of FLT3 mutations and promyelocytic leukaemia-breakpoint on clinical characteristics and prognosis in acute promyelocytic leukaemiaFlorian Kuchenbauer, Claudia Schoch, Wolfgang Kern, et al.
Genes, Chromosomes & Cancer|April 23, 2005
Acute myeloid leukemia with a complex aberrant karyotype is a distinct biological entity characterized by genomic imbalances and a specific gene expression profileClaudia Schoch, Wolfgang Kern, Alexander Kohlmann, et al.
Blood|September 1, 2010
IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 statusSusanne Schnittger, Claudia Haferlach, Madlen Ulke, et al.
Cancer|July 2, 2009
The impact of cytomorphology, cytogenetics, molecular genetics, and immunophenotyping in a comprehensive diagnostic workup of myelodysplastic syndromesUlrike Bacher, Torsten Haferlach, Wolfgang Kern, et al.
Blood Cancer Journal|May 9, 2026
The clinical relevance of sole loss of chromosome Y in myeloid neoplasmsSandra Huber, Stephan Hutter, Manja Meggendorfer, et al.
Leukemia & Lymphoma|August 3, 2012
Patients with therapy-related myelodysplastic syndromes and acute myeloid leukemia share genetic features but can be separated by blast counts and cytogenetic risk profiles into prognostically relevant subgroupsUlrike Bacher, Claudia Haferlach, Tamara Alpermann, et al.
Cancer Genetics and Cytogenetics|December 16, 2010
Correlation of cytomorphology, immunophenotyping, and interphase fluorescence in situ hybridization in 381 patients with monoclonal gammopathy of undetermined significance and 301 patients with plasma cell myelomaUlrike Bacher, Torsten Haferlach, Wolfgang Kern, et al.
Blood|July 31, 2004
Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemiaWolfgang Kern, Daniela Voskova, Claudia Schoch, et al.
Cancer Genetics and Cytogenetics|November 6, 2004
Cytogenetic profile in de novo acute myeloid leukemia with FAB subtypes M0, M1, and M2: a study based on 652 cases analyzed with morphology, cytogenetics, and fluorescence in situ hybridizationMirjam Klaus, Torsten Haferlach, Susanne Schnittger, et al.
Pageof 60

Showing results (121-130 of 596) with videos related to

Sort By:
Pageof 60
Medizinische Klinik (Munich, Germany : 1983)|January 20, 2007
[Microarrays and gene expression profiling for the diagnosis in leukemia. From research studies to routine application]Torsten Haferlach, Ulrike Bacher, Alexander Kohlmann, et al.
British Journal of Haematology|July 21, 2005
Impact of FLT3 mutations and promyelocytic leukaemia-breakpoint on clinical characteristics and prognosis in acute promyelocytic leukaemiaFlorian Kuchenbauer, Claudia Schoch, Wolfgang Kern, et al.
Genes, Chromosomes & Cancer|April 23, 2005
Acute myeloid leukemia with a complex aberrant karyotype is a distinct biological entity characterized by genomic imbalances and a specific gene expression profileClaudia Schoch, Wolfgang Kern, Alexander Kohlmann, et al.
Blood|September 1, 2010
IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 statusSusanne Schnittger, Claudia Haferlach, Madlen Ulke, et al.
Cancer|July 2, 2009
The impact of cytomorphology, cytogenetics, molecular genetics, and immunophenotyping in a comprehensive diagnostic workup of myelodysplastic syndromesUlrike Bacher, Torsten Haferlach, Wolfgang Kern, et al.
Blood Cancer Journal|May 9, 2026
The clinical relevance of sole loss of chromosome Y in myeloid neoplasmsSandra Huber, Stephan Hutter, Manja Meggendorfer, et al.
Leukemia & Lymphoma|August 3, 2012
Patients with therapy-related myelodysplastic syndromes and acute myeloid leukemia share genetic features but can be separated by blast counts and cytogenetic risk profiles into prognostically relevant subgroupsUlrike Bacher, Claudia Haferlach, Tamara Alpermann, et al.
Cancer Genetics and Cytogenetics|December 16, 2010
Correlation of cytomorphology, immunophenotyping, and interphase fluorescence in situ hybridization in 381 patients with monoclonal gammopathy of undetermined significance and 301 patients with plasma cell myelomaUlrike Bacher, Torsten Haferlach, Wolfgang Kern, et al.
Blood|July 31, 2004
Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemiaWolfgang Kern, Daniela Voskova, Claudia Schoch, et al.
Cancer Genetics and Cytogenetics|November 6, 2004
Cytogenetic profile in de novo acute myeloid leukemia with FAB subtypes M0, M1, and M2: a study based on 652 cases analyzed with morphology, cytogenetics, and fluorescence in situ hybridizationMirjam Klaus, Torsten Haferlach, Susanne Schnittger, et al.
Pageof 60